B.A., Rutgers University; M.S., University of Wisconsin-Madison; Ph.D., University of Massachusetts Amherst
Area(s) of Specialization:
clinical trials, public health, health services research, biostatistics, epidemiology
Scott Chasan-Taber, PhD is a biostatistician with over 25 years of experience in healthcare analytics including strategic development and operational innovation in both clinical and health services research. He has played a major role in global regulatory filings and lifecycle management of several pharmaceutical products and medical devices.
Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM. Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results from Two Multinational, Randomized, Controlled Trials. Clin Infect Dis. 2014 May; 58(10).
Chasan-Taber S, Rimm EB, Stampfer MJ, Speigelman D, Colditz G, Giovannucci E, Ascherio A, Willett WC. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire for Male Health Professionals. Epidemiology 1996; 7:81-86.
Weissman JS, Levin K, Chasan-Taber S, Massagli MP, Seage GR, Scampini L, Epstein AM. The Validity of Self-Reported Health Care Utilization by AIDS Patients AIDS 1996; 10:775-783.
Hosmer DW, Taber SM, Lemeshow S. The Importance of Assessing the Fit of Logistic Regression Models: A Case Study. American Journal of Public Health 1991; 81:1630-1635.
Lemeshow S, Taber SM. Lot Quality Assurance Sampling: Single and Double Sampling Plans. World Health Statistics Quarterly 1991; 44:115-132.